ClinicalTrials.gg
CompletedNCT01475721AUSTRIUpdated Aug 6, 2018Results posted

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

A Phase 4 interventional study of ADVAIR 100/50mcg and ADVAIR 250/50mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 808 sites in 33 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-08-06.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11,751
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
Largest of 146
11,751 · median 100
Started
2011
with 7 others
Phase 4
52 of 147
1 open now
Registered
82nd of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one has the largest enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2011, is one of 52 in phase 4, and was the 82nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.

ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.

Read the detailed description

Progress of Enrollment, Updated Annually: This study has been completed and the final clinical study report was submitted to the FDA in January of 2016. This is the final update, as this study is complete.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • ADVAIR
  • Asthma
  • safety
  • FLOVENT
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided consent to participate in the study
  • Male or female, 12 years of age and older
  • Clinical diagnosis of asthma for at least 1 year prior to the randomization
  • Clinic PEF of greater than or equal to 50% of predicted normal value
  • Subject must be appropriately using one of the treatments for asthma listed in the protocol
  • Subject must be able to complete the asthma control questionnaire, daily questions about asthma, and use a DISKUS inhaler
  • Subject must have history of at least 1 asthma exacerbation including one of the following in the year prior to randomization:
  • requiring treatment with systemic
  • an asthma-related hospitalization

Exclusion criteria

Exclusion Criteria:

  • History of life threatening asthma defined for this protocol as asthma episode that required intubation and/or was associated with hypercapnea requiring non-invasive ventilatory support
  • Concurrent respiratory disease other than asthma
  • Current evidence of, or ever been told by a physician that they have chronic bronchitis, emphysema, or .
  • Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine
  • Presence of a bacterial or viral respiratory infection that is not resolved at randomization
  • An asthma exacerbation requiring systemic corticosteriods within 4 weeks of randomization or more than 4 separate exacerbations in the 12 months preceding randomization
  • More than 2 hospitalizations for treatment of asthma in the 12 months preceding randomization
  • Subject must not meet unstable asthma severity criteria as listed in the protocol
  • Potent cytochrome P450 3A4 () inhibitors within the last 4 weeks (e.g., ritonavir, ketoconazole, itraconzole)
  • Pregnancy, breast-feeding or planned pregnancy during the study
  • A Child in Care (CiC) is a child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
11,751 participants (actual)

Study arms

  • Experimental
    ADVAIR 100/50mcg

    experimental drug

    Drug: ADVAIR 100/50mcg

  • Experimental
    ADVAIR 250/50mcg

    experimental drug

    Drug: ADVAIR 250/50mcg

  • Experimental
    ADVAIR 500/50mcg

    experimental drug

    Drug: ADVAIR 500/50mcg

  • Active comparator
    FLOVENT 100mcg

    active comparator

    Drug: FLOVENT 100mcg

  • Active comparator
    FLOVENT 250mcg

    active comparator

    Drug: FLOVENT 250mcg

  • Active comparator
    FLOVENT 500mcg

    active comparator

    Drug: FLOVENT 500mcg

Interventions

  • DrugADVAIR 100/50mcg

    fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

    Also known as: FSC 100/50

  • DrugADVAIR 250/50mcg

    fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

    Also known as: FSC 250/50

  • DrugADVAIR 500/50mcg

    fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months

    Also known as: FSC 500/50

  • fluticasone propionate (100) twice daily (AM and PM) for 6 months

    Also known as: FP 100

  • fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

    Also known as: FP 250

  • fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months

    Also known as: FP 500

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)

    Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility. Probability of having event was summarized with Kaplan-Meier estimates.Hazard ratio, confidence interval, and p-value are from a stratified Cox proportional hazard model, using randomization stratum as the stratification factor. The 95% CI provided in the table is actually the 95.

    Time frame: From Day 1 up to 26 weeks

  2. Number of Participants Experiencing at Least One Asthma Exacerbation

    An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.

    Time frame: From Day 1 up to 26 weeks

Secondary outcomes

  1. Number of Participants Experiencing at Least One Asthma Related Hospitalization , Endotracheal Intubation and Death

    Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility.

    Time frame: From Day 1 up to 26 weeks

  2. Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation

    An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.

    Time frame: From Day 1 up to 26 weeks

  3. Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours

    Rescue medication included albuterol/salbutamol used to treat acute asthma were reported as puffs per 24 hours over a period of 6 months.

    Time frame: From Day 1 up to 26 weeks

07

Results

Posted Jan 14, 2016

Participant flow

Study duration was 29 weeks, comprised of a randomization visit followed by a treatment period of 26 weeks and a 1 week follow-up phone call. Participants were assessed for eligibility at screening up to 15 days prior to randomization.

Participant flow — Overall Study
MilestoneFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Started58345845
Completed58235831
Not completed1114
Withdrew: Death36
Withdrew: Withdrawal by subject88

Outcome measures

PrimaryNumber of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)

Composite endpoint was defined as clinically relevant endpoint that is constructed from combinations of other clinically relevant endpoints of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death). Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility. Probability of having event was summarized with Kaplan-Meier estimates.Hazard ratio, confidence interval, and p-value are from a stratified Cox proportional hazard model, using randomization stratum as the stratification factor. The 95% CI provided in the table is actually the 95.

Time frame:
From Day 1 up to 26 weeks
Reported as:
Number · Participants
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)
ParticipantsFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)3433
Statistical analysis
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.003 · Hazard ratio (hr): 1.029 · 95% CI 0.638 to 1.662
PrimaryNumber of Participants Experiencing at Least One Asthma Exacerbation

An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.

Time frame:
From Day 1 up to 26 weeks
Reported as:
Number · Participants
Number of Participants Experiencing at Least One Asthma Exacerbation
ParticipantsFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Number of Participants Experiencing at Least One Asthma Exacerbation480597
Statistical analysis
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.203 · Hazard ratio (hr): 0.834 · 95% CI 0.630 to 1.103Analysis of time to first exacerbation in efficacy subgroup: Subjects not well-controlled on prior ICS or non-LABA therapy.
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.188 · Hazard ratio (hr): 0.839 · 95% CI 0.645 to 1.090Analysis of time to first exacerbation in efficacy subgroup: Subjects not well-controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.002 · Hazard ratio (hr): 0.764 · 95% CI 0.645 to 0.905Analysis of time to first exacerbation in efficacy subgroup: Subjects controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.071 · Hazard ratio (hr): 0.682 · 95% CI 0.451 to 1.034Analysis of time to first exacerbation in efficacy subgroup: Subjects controlled on prior ICS therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.373 · Hazard ratio (hr): 0.878 · 95% CI 0.659 to 1.170Analysis of number of asthma exacerbations in efficacy subgroup: Subjects not well-controlled on prior ICS or non-LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.271 · Hazard ratio (hr): 0.864 · 95% CI 0.665 to 1.122Analysis of number of asthma exacerbations in efficacy subgroup: Subjects not well-controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.001 · Hazard ratio (hr): 0.755 · 95% CI 0.637 to 0.895Analysis of number of asthma exacerbations in efficacy subgroup: Subjects controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.075 · Hazard ratio (hr): 0.687 · 95% CI 0.454 to 1.040Analysis of number of asthma exacerbations in efficacy subgroup: Subjects controlled on prior ICS therapy
SecondaryNumber of Participants Experiencing at Least One Asthma Related Hospitalization , Endotracheal Intubation and Death

Hospitalization was defined as an inpatient stay or a ≥24-hour stay in an observation area in an emergency department or other equivalent facility.

Time frame:
From Day 1 up to 26 weeks
Reported as:
Number · Participants
Number of Participants Experiencing at Least One Asthma Related Hospitalization , Endotracheal Intubation and Death
ParticipantsFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Hospitalization3433
Endotracheal intubation02
Death00
SecondaryNumber of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation

An asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least three days or an inpatient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.

Time frame:
From Day 1 up to 26 weeks
Reported as:
Number · Participants
Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation
ParticipantsFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation6684
Statistical analysis
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.123 · Hazard ratio (hr): 0.776 · 95% CI 0.562 to 1.071
SecondaryMean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours

Rescue medication included albuterol/salbutamol used to treat acute asthma were reported as puffs per 24 hours over a period of 6 months.

Time frame:
From Day 1 up to 26 weeks
Reported as:
Mean · Number of Puffs
Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours
Number of PuffsFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours0.90 ± 0.0181.09 ± 0.020
Statistical analysis
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = <0.001 · Mean difference (final values): -0.263 · 95% CI -0.385 to -0.141Efficacy subgroup: Subjects not well-controlled on prior ICS or non-LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.003 · Mean difference (final values): -0.222 · 95% CI -0.369 to -0.076Efficacy subgroup: Subjects not well-controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = <0.001 · Mean difference (final values): -0.172 · 95% CI -0.238 to -0.106Efficacy subgroup: Subjects controlled on prior ICS+LABA therapy
  • Fluticasone Propionate/Salmeterol Combination (FSC) vs Fluticasone Propionate (FP) · Regression, Cox · p = 0.251 · Mean difference (final values): -0.080 · 95% CI -0.216 to 0.056Efficacy subgroup: Subjects controlled on prior ICS therapy

Adverse events

Collected over Serious adverse events (SAEs) and non-serious events (AEs) were collected from post-randomization, throughout the treatment period of 26 weeks up to a 1-week follow-up phone call (27 Weeks).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Propionate/Salmeterol Combination (FSC)—134/5,834 (2.3%)46/5,834 (0.8%)
Fluticasone Propionate (FP)—125/5,845 (2.1%)75/5,845 (1.3%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
AsthmaRespiratory, thoracic and mediastinal disorders30/583428/5845
PneumoniaInfections and infestations8/58348/5845
DyspnoeaRespiratory, thoracic and mediastinal disorders1/58345/5845
Cerebrovascular accidentNervous system disorders4/58343/5845
Chest painGeneral disorders2/58344/5845
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/58344/5845
AnaemiaBlood and lymphatic system disorders3/58341/5845
Atrial fibrillationCardiac disorders3/58340/5845
PyelonephritisInfections and infestations3/58340/5845
Diabetes mellitusMetabolism and nutrition disorders3/58340/5845
Most frequent other events
Most frequent other events
EventFluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)
AsthmaRespiratory, thoracic and mediastinal disorders46/583475/5845

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)Total
Mean43.4 ± 17.4543.4 ± 17.2843.4 ± 17.36
Sex: Female, Male
Sex: Female, Male(Participants)Fluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)Total
Female385138987749
Male198319473930
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fluticasone Propionate/Salmeterol Combination (FSC)Fluticasone Propionate (FP)Total
Missing336
African American/African Heritage8708561726
American Indian/Alaska native109116225
Asian-Central/South Asian Heritage364581
Asian-East Asian Heritage9488182
Japanese Heritage437
Asian-South East Asian Heritage234224458
Native Hawaiian or other Pacific Islander81018
White-Arabic/North African Heritage222143
White-White/Caucasian/European Heritage435243888740
Multiple10291193
08

Study locations

808 sites
  • GSK Investigational Site
    Athens, Alabama 35611, United States
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Birmingham, Alabama 35216, United States
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Florence, Alabama 35630, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Montgomery, Alabama 36109, United States
  • GSK Investigational Site
    Pell City, Alabama 35128, United States
  • GSK Investigational Site
    Scottsboro, Alabama 35768, United States
  • GSK Investigational Site
    Toney, Alabama 35773, United States
  • GSK Investigational Site
    Tuscaloosa, Alabama 35401, United States
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Flagstaff, Arizona 86001, United States
  • GSK Investigational Site
    Goodyear, Arizona 85395, United States
  • GSK Investigational Site
    Green Valley, Arizona 85614, United States
  • GSK Investigational Site
    Mesa, Arizona 85203, United States
  • GSK Investigational Site
    Mesa, Arizona 85206, United States
  • GSK Investigational Site
    Peoria, Arizona 85381, United States
  • GSK Investigational Site
    Phoenix, Arizona 85023, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Phoenix, Arizona 85051, United States
  • GSK Investigational Site
    Phoenix, Arizona 92120-4915, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85255, United States
  • GSK Investigational Site
    Sierra Vista, Arizona 85635, United States
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Anaheim, California 92804, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Dinuba, California 93618, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Granada Hills, California 91344, United States
  • GSK Investigational Site
    Harbor City, California 90710, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Huntington Park, California 90255, United States
  • GSK Investigational Site
    Lomita, California 90717, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Long Beach, California 90807, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90057, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Napa, California 94558, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Oxnard, California 93030, United States
  • GSK Investigational Site
    Paramount, California 90723, United States
  • GSK Investigational Site
    Pismo Beach, California 93449, United States
  • GSK Investigational Site
    Pomona, California 91767, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    Roseville, California 95678, United States
  • GSK Investigational Site
    Sacramento, California 95823, United States
  • GSK Investigational Site
    Sacramento, California 95841, United States
  • GSK Investigational Site
    San Gabriel, California 91776, United States
  • GSK Investigational Site
    San Jose, California 95116, United States
  • GSK Investigational Site
    San Marcos, California 92078-4081, United States
  • GSK Investigational Site
    San Marino, California 91108, United States
  • GSK Investigational Site
    San Ramon, California 94583, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Ventura, California 93003, United States
  • GSK Investigational Site
    Vista, California 92083, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    West Sacramento, California 95691, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80906, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80907, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80909, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80922, United States
  • GSK Investigational Site
    Denver, Colorado 80206, United States
  • GSK Investigational Site
    Fort Collins, Colorado 80538, United States
  • GSK Investigational Site
    Golden, Colorado 80401, United States
  • GSK Investigational Site
    Thornton, Colorado 80233, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    Danbury, Connecticut 06810, United States
  • GSK Investigational Site
    Milford, Connecticut 06460, United States
  • GSK Investigational Site
    Waterbury, Connecticut 06708, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Boynton Beach, Florida 33437, United States
  • GSK Investigational Site
    Brandon, Florida 33511, United States
  • GSK Investigational Site
    Clearwater, Florida 33756, United States
  • GSK Investigational Site
    Clearwater, Florida 33759, United States
  • GSK Investigational Site
    Cocoa, Florida 32927, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Destin, Florida 32541, United States
  • GSK Investigational Site
    Doral, Florida 33166, United States
  • GSK Investigational Site
    Doral, Florida 33172, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Hialeah, Florida 33016, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Jupiter, Florida 33458, United States
  • GSK Investigational Site
    Maitland, Florida 32751, United States
  • GSK Investigational Site
    Melbourne, Florida 32935, United States
  • GSK Investigational Site
    Miami, Florida 33015, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Miami, Florida 33165, United States
  • GSK Investigational Site
    Miami, Florida 33175, United States
  • GSK Investigational Site
    New Port Richey, Florida 34652, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Orlando, Florida 32811, United States
  • GSK Investigational Site
    Orlando, Florida 32822, United States
  • GSK Investigational Site
    Pensacola, Florida 32514, United States

Showing the first 100 of 808 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Busse W, Stempel D, Aggarwal B, Boucot I, Forth R, Raphiou I, Rabe KF, Reddel HK. Insights from the AUSTRI study on reliever use before and after asthma exacerbations. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1916-1918.e2. doi: 10.1016/j.jaip.2022.03.029. Epub 2022 Apr 9. No abstract available. PubMed 35413473 ↗
  • Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, Buaron KS, Pascoe SJ; AUSTRI Investigators. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med. 2016 May 12;374(19):1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6. PubMed 26949137 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2011 to primary completion in Jun 2015, 43 months.

Results were first posted in Jan 2016, 6 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 43 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2011
First posted
Nov 21, 2011
StartActual
Nov 18, 2011
Primary completionActual
Jun 23, 2015
CompletionActual
Jun 23, 2015
Results first posted
Jan 14, 2016
Last update
Aug 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01475721
Lead sponsor
GlaxoSmithKline
Collaborators
Parexel
Responsible party
Sponsor
First posted
Nov 21, 2011
Start date
Nov 18, 2011
Primary completion
Jun 23, 2015
Completion
Jun 23, 2015
Results posted
Jan 14, 2016
Last update
Aug 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion